Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aritro Nath

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Journal of Clinical Medicine|January 8, 2025
Single-Cell Transcriptomics Sheds Light on Tumor Evolution: Perspectives from City of Hope's Clinical Trial TeamsPatrick A Cosgrove, Andrea H Bild, Thanh H Dellinger, et al.
Oncotarget|February 1, 2018
Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profileFan Wang, Jeremy T-H Chang, Zhenyu Zhang, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2024
A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bindRena Emond, Jeffrey West, Vince Grolmusz, et al.
International Journal of Molecular Sciences|October 23, 2021
Long Non-Coding RNA <i>ANRIL</i> as a Potential Biomarker of Chemosensitivity and Clinical Outcomes in OsteosarcomaAdam M Lee, Asmaa Ferdjallah, Elise Moore, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|December 5, 2024
Unveiling the potential of gene editing techniques in revolutionizing Cancer treatment: A comprehensive overviewPankaj Garg, Gargi Singhal, Siddhika Pareek, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 25, 2019
Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genesAritro Nath, Eunice Y T Lau, Adam M Lee, et al.
Elife|September 29, 2023
ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancerElena Farmaki, Aritro Nath, Rena Emond, et al.
Molecular Systems Biology|March 27, 2026
A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bindRena Emond, Jeffrey West, Vince K Grolmusz, et al.
Cancer Cell International|June 23, 2020
Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line modelVince Kornél Grolmusz, Jinfeng Chen, Rena Emond, et al.
Genome Research|August 30, 2017
Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studiesPaul Geeleher, Zhenyu Zhang, Fan Wang, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Journal of Clinical Medicine|January 8, 2025
Single-Cell Transcriptomics Sheds Light on Tumor Evolution: Perspectives from City of Hope's Clinical Trial TeamsPatrick A Cosgrove, Andrea H Bild, Thanh H Dellinger, et al.
Oncotarget|February 1, 2018
Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profileFan Wang, Jeremy T-H Chang, Zhenyu Zhang, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2024
A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bindRena Emond, Jeffrey West, Vince Grolmusz, et al.
International Journal of Molecular Sciences|October 23, 2021
Long Non-Coding RNA <i>ANRIL</i> as a Potential Biomarker of Chemosensitivity and Clinical Outcomes in OsteosarcomaAdam M Lee, Asmaa Ferdjallah, Elise Moore, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|December 5, 2024
Unveiling the potential of gene editing techniques in revolutionizing Cancer treatment: A comprehensive overviewPankaj Garg, Gargi Singhal, Siddhika Pareek, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 25, 2019
Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genesAritro Nath, Eunice Y T Lau, Adam M Lee, et al.
Elife|September 29, 2023
ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancerElena Farmaki, Aritro Nath, Rena Emond, et al.
Molecular Systems Biology|March 27, 2026
A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bindRena Emond, Jeffrey West, Vince K Grolmusz, et al.
Cancer Cell International|June 23, 2020
Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line modelVince Kornél Grolmusz, Jinfeng Chen, Rena Emond, et al.
Genome Research|August 30, 2017
Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studiesPaul Geeleher, Zhenyu Zhang, Fan Wang, et al.
Pageof 5